Global Cancer Immunotherapy Market by Therapy; by Applications; by End User (Hospitals & Clinics, Cancer Research Centers); by Region (North America, Europe, Asia-pacific, Latin America, Middle East Africa): Global Forecasts 2021 To 2027

The Global Cancer Immunotherapy Market was valued at USD 86 Bn in 2020 and is expected to reach USD 192.3 Bn by 2027, with a growing CAGR of 12.2% during the forecast period.

Global Cancer Immunotherapy Market Definition

Cancer immunotherapy is used to treat cancer patients by providing artificial stimulation to the immune system. This helps to enhance the immune system and gain the ability to fight the disease amongst the patients. In this therapy, an individual’s immune system is used to fight against cancer. Immunotherapy is expected to hold huge potential for curing cancers. Immunotherapy can also be used as standalone therapy along with other cancer treatments.  

Cancer Immunotherapy Market

Global Cancer Immunotherapy Market Dynamics

The driving factors influencing the global cancer immunotherapy market include increasing incidences of cancer diseases such as lung cancer, blood cancer, and rising approval for innovative immunotherapy drug forms such as a vaccines and adjuvants. For instance, according to the clinical trial application no. NCT04267848, non-small-cell lung cancer hold the significant mortality every year across the world. After the successful incision of cancerous cells, platinum-based chemotherapy is expected to enhance the survival of patients till the recurrence of diseases. Adjuvant immunotherapy is expected to hold high efficacy and efficiency to improve the health of the patient which is expected to increase in demand for cancer immunotherapy during the forecast period. Moreover, ALCHEMIST, a clinical trial platform offered by the National Cancer Institute aimed to support and evaluate the chemotherapy plus pembrolizumab. This is supported by the pembrolizumab to the standard of care adjuvant platinum-based chemotherapy which is expected to pull the growth of adjuvant-based immunotherapy in the cancer immunotherapy demand in the market during the forecast period. Such ongoing research on the adjuvant chemotherapies and cancer vaccines are expected to propel the growth of the cancer immunotherapy demand during the forecast period. Furthermore, rising healthcare expenditure, government spending on R&D for cancer therapies, and growing number of clinical trials associated with cancer immunotherapy is expected to leverage the growth of the cancer immunotherapy demand in the ecosystem during the forecast period.

In addition, growing collaborations among pharmaceutical companies for the development and manufacturing of cancer immunotherapies are expected to boost the cancer immunotherapy demand in the market during the forecast period. For instance, in December 2021, Boehringer Ingelheim (Germany) collaborated with Enara Bio (Oxford, Oxfordshire, England) and signed licensing agreement to discover, design, and develop Novel Shared Antigens for Cancer Immunotherapy. This collaboration is expected to focus on gastrointestinal and lungs cancer and strengthen the position of Boehringer Ingelheim in the cancer vaccine and T-cells spaces. However, stringent regulatory policies for therapy approvals are expected to hinder the growth of cancer immunotherapy demand during the forecast period.

Global Cancer Immunotherapy Market Segmentation:

By Therapy

  • Monoclonal Antibodies
  • Immunomodulators
  •  Cancer Vaccines
  • Immune Check Point Inhibitors

By Applications

  • Prostate Cancer
  • Skin Cancer
  • Lung Cancer
  • Breast Cancer
  •  Others

By End User

  • Hospitals & Clinics
  • Cancer Research Centers

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Company Profiles and Competitive Intelligence

The key players operating in the cancer immunotherapy market are:

  • Amgen, Inc.
  • Astrazeneca
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lily And Company
  • F. Hoffmann-La Roche, Ltd
  • Pfizer, Inc.
  • Johnson & Johnson
  • Merck KGAA
  • Novartis AG
  • Celgene Corporation
  • Incyte Corporation
  • Juno Therapeutics
  • Bluebird bio
  • Celldex Therapeutics
  • Tesaro, Inc
  • Kite Pharm
  • NewLink Genetics
  • ZIOPHARM Oncology

Based on therapy, monoclonal antibodies segment is expected to hold largest market share during the forecast period due to the benefits offered by monoclonal antibodies in cancer treatment such as it helps to turn the immune system in the cancer

Based on therapy, cancer immunotherapy market is segmented into monoclonal antibodies, immunomodulators, cancer vaccines, and immune check point inhibitors. Monoclonal antibodies held largest market share in 2020 due to presence of large volume of cancer patients. This therapy is expected to dominate the market during forecast period due to rising demand for safe and effective cancer therapy which would trigger person’s own immunity system to fight against the cancer. Moreover, increasing usage of monoclonal antibodies for targeted therapy is expected to boost the cancer immunotherapy demand in the ecosystem during the forecast period. For instance, rituximab which binds with CD20 on B cells that tend to kill cells through immune system and helps to fight against cancer cells. Furthermore, increasing research activities related to the development of monoclonal antibodies such as Isatuximab (Multiple Myeloma, 2020) is expected to fuel the growth of the segment in the cancer immunotherapy market during the forecast period.

Based on applications, lung cancer segment is expected to contribute highest market growth during the forecast period due to increasing developments of immunotherapy procedures especially for non-small cell lung cancers

Based on applications, cancer immunotherapy market is broadly segmented into prostate cancer, lung cancer, skin cancer, and breast cancer. Lung cancer segment accounted for maximum market share in 2020 owing to increase in number of patients with lung cancer. According to WHO (World Health Organization) 2020, one-third of death across the world are due to consumption of Tobacco or alcohol or lack of physical activities which directly lead to the lung cancer. From out of 10 Mn deaths across the globe, ~2Mn deaths are reported with lung cancer. Such rising incidences of lung cancer across the globe is expected to fuel the growth of the cancer immunotherapy demand in the market during the forecast period. Furthermore, lung cancer segment is expected to observe high market growth during the forecast period due to rising consumption of smoking in the population.

Smoking is considered as primary risk factor and leading cause for lung cancer. In addition, growing number of FDA approvals for cancer immunotherapy is expected to pull the growth of cancer immunotherapy demand in the market during the forecast period. For instance, in March 2019, Roche (Switzerland) received US FDA approval for drug Atezolizumab (Tecentriq) which is used for the treatment of non-small cell lung cancer. Such therapy approvals are expected to trigger the growth of the cancer immunotherapy market during the forecast period.

Based on region, North America is expected to dominate the growth of the market during the forecast period due to increasing developments in healthcare infrastructure in this region

Based on region, North America is expected to hold largest market share during the forecast period due to rising number of cancers affected patients and increasing prevalence of cancer due to change in lifestyle. For instance, according to The Cancer Atlas, cancer is the leading cause of death in Canada. More than ~1.9 Mn are the new emerging cancer cases in North America. Such rising incidences of cancer cases are expected to leverage the growth of the cancer immunotherapy demand in the market during the forecast period. Furthermore, growing government initiatives in the terms of funds and awareness are expected to fuel the growth of the market during the forecast period.

The report also provides in-depth analysis of Cancer Immunotherapy market dynamics such as drivers, restraints, opportunities, and challenges

Drivers

  • Rising number of cancer cases across the globe
  • Emergence of innovative therapies for cancer treatment
  • Increasing geriatric population
  • Growing inclination towards western lifestyle

Restraints

  • High therapy developmental cost
  • Stringent government regulations for therapy approvals

Opportunity

  • Increase in development and commercialization of new cancer therapies
  • Exploration of untapped market in developing countries such as India and China
  • Rising need for clinical evidence for therapy to improved patient convenience for treatments

Challenges

  • Patients receiving immunotherapy tend to show side effects such as allergic reactions, pain, and swelling
  • Difficulty in building pre-clinical model for cancer research

COVID-19 Impact on the Cancer Immunotherapy Market Analysis

Covid-19 has created havoc on the healthcare sector across the globe. Cancer immunotherapy market is negatively affected by the pandemic. Due to the burden of covid-19 cases on the hospitals and clinics, cancer affected patients which were not critical were kept on hold. Priority was given to the covid infected patients across the globe. Moreover, drug development process and clinical trials related to the cancer therapy were delayed due to continuous rising covid cases. However, the market is expected to flourish in coming years after normalization of the situation across the world. As covid-19 impacted the health of the patients with lung or gastrointestinal cancer, the market is expected to grow post-covid and anticipates the growth of the cancer immunotherapy during the forecast period.

 The report also provides an in-depth analysis of key trends in cancer immunotherapy market

Sr. No. Trends Impact
1 Growing attention of researchers towards new cancer methodologies such as CAR T-cells, immune checkpoint inhibitors, and HPV vaccination Positive
2 Rising interest of researchers towards functionalized nano system for targeted therapy Positive

 The report also provides an in-depth analysis of recent news developments and investments

  • In March 2021, Parker Institute for Cancer Immunotherapy (US) and Cancer Research Institute (US) announced the beginning of open label platform study procedure with first dose in the group of patients for First-line Pancreatic Cancer Platform trial. This clinical trial is expected to use innovative combination of therapies in the parallel. This methodology represents new model of end-to-end drug development that is expected to provide favourable therapeutic combinations to the market from the bench to bedside.
  • In May 2021, Amgen (US) received US FDA approval for LUMAKRAS™ (Sotorasib) for the treatment of KRAS G12C-mutated cancer disease in the adults. This cancer is expected to be the metastatic non-small cell lung cancer who have history of receiving at least one prior systemic therapy. This approval is expected to be the addition of anti-cancer therapy in the Amgen’s therapy portfolio which is further expected to enhance their leadership the cancer immunotherapy market.

The unique insights provided by this report also includes the following:

  • In-depth Value Chain Analysis
  • Opportunity Mapping
  • Sector Snapshot
  • Key Players Positioning Matrix
  • Regulatory Scenario
  • Strategies Adopted-Benchmarking Heat Map
  • Market Trends
  • Covid-19 Impact Analysis
  • Product Comparison
  • Pre & Post COVID 19 Impacts on Cancer Immunotherapy Market
  • Competitive Landscape

Frequently Asked Questions (FAQs)

The global cancer immunotherapy market was valued at USD 86 Bn in 2020 and is anticipated to reach USD 192.3 Bn by 2027.

The global cancer immunotherapy market is estimated to grow at a compound annual growth rate (CAGR) of 12.2% during forecast period.

In the base year 2020, North America accounted for the highest share in the market.

Stringent government policies for therapy approvals restraint the growth of global cancer immunotherapy market.

As per expert opinions, increase in number of cancer patients, changing lifestyle of population, rising number of R&D and clinical trials for novel cancer therapy development will drive the growth of global cancer immunotherapy market.

Few key players include, but not limit up to: Amgen, Inc., Astrazeneca, Bayer AG, Bristol-Myers Squibb Company, Eli Lily and Company, F. Hoffmann-La Roche, Ltd, Pfizer, Inc., Johnson & Johnson, Merck KGAA, Novartis AG, Celgene Corporation, and Incyte Corporation.

Related Reports

Need specific market information ?

Ask for free product review call with the author

Share your specific research requirements for a customized report

Request for due diligence and consumer centric studies

Request for study updates, segment specific and country level reports

Introduction

  1. Product Outline
  2. What is Cancer Immunotherapy?
  3. Analysis of Cancer Immunotherapy Market
  4. Covid -19 Impact
  5. Market Dynamics
    1. Drivers
    2. Restraints
    3. Opportunities
    4. Threats
  6. Technology Overview
  7. Regulatory Landscape for Cancer Immunotherapy Market
    1. Regulations and Standards
  8. Cancer Immunotherapy Market by Therapy
    1. Monoclonal Antibodies
    2.  Cancer Vaccines
    3. Immunomodulators
    4. Immune Check Point Inhibitors
  9. Cancer Immunotherapy Market by Applications
    1. Prostate Cancer
    2. Lung Cancer
    3. Skin Cancer
    4. Breast Cancer
    5.  Others
  10. Cancer Immunotherapy Market by End User
    1. Hospitals & Clinics
    2. Cancer Research Centers
  11. Regional Analysis
    1. North America
      1. US
      2. Canada
    2. Europe
      1. Germany
      2. UK
      3. France 
      4. Spain  
      5. Italy  
      6. Rest Of Europe
    3. Asia Pacific
      1. China
      2. India
      3. Japan
      4. Australia
      5. Rest Of Asia Pacific
    4. Latin America
      1. Brazil
      2. Colombia
      3. Rest of Latin America
    5. Middle East Africa (MEA)
      1. GCC
      2. Rest of MEA
  12. Key Strategic Insights
  13. Key Market Trends / Recent Developments
    1. New Applications
    2. Emerging Technologies
    3. Opportunity Mapping
    4. Critical Success Factors
    5. Environmental Impact and Sustainability Issues
    6. Customer Preferences
  14. Competitive Scenario
    1. Mergers and Acquisitions
    2. Investments
    3. Joint Ventures
    4. New Product Launches
    5. Presence of Players by Geographies
  15. Key global players
    1. Amgen, Inc.
    2. Astrazeneca
    3. Bayer AG
    4. Bristol-Myers Squibb Company
    5. Eli Lily And Company
    6. F. Hoffmann-La Roche, Ltd
    7. Pfizer, Inc.
    8. Johnson & Johnson
    9. Merck KGAA
    10. Novartis AG
    11. Celgene Corporation
    12. Incyte Corporation
    13. Juno Therapeutics
    14. Bluebird bio
    15. Celldex Therapeutics
    16. Others

Choose License

License Type
Ask for Customization

Why Choose AllTheResearch?

  • Monthly market updates for 6 months
  • Online access of reports
  • Options to buy sections of report
  • Critically analysed research on Quadrant Positioning of your company.
  • Syndicated report along with a supplementary report with objective-based study
  • Get profiled in the reports.Expanding your visibility across our network of readers and viewers
  • We provide local market data in local language on request
  • A complementary co-branded white paper
  • Flat consulting fee based exclusive studies. Consult at the price of syndicate
  • Access to expert team for free transaction advisory service.
Speak to Analyst

Quick Inquiry

Follow Us

Choose License

License Type
Ask for Customization